Articles on Breast Cancer
What is HER2-positive breast cancer?
HER2 (human epidermal growth factor receptor 2) is a transmembrane tyrosine kinase receptor and is expressed by, and involved in the growth of, some cancer cells. For example, HER2 is overexpressed in 18% to 20% of invasive breast cancers and affects treatment as well as prognosis of breast cancers.
- In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein.
- HER2 is a growth-promoting protein located on the surface of some cancer cells.
- HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative.
What causes HER2-positive breast cancer?
Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
What tests detect HER2?
All patients with invasive breast cancer should have their tumor cells tested for HER2. Medical professionals routinely perform this test in the pathology laboratory at the time of diagnosis, using the sample of your breast tissue removed for diagnosis. The testing for HER2 can involve one or more of the following tests.
Health care professionals may use either immunohistochemistry (IHC) to identify the HER2 protein or in-situ hybridization (ISH) testing to look for the gene.
- IHC test: This test shows if there is too much HER2 protein in the cancer cells and is graded 0 to 3.
- FISH test: This test evaluates if there are too many copies of the HER2 gene in the cancer cells. This test is either positive or negative.
- SPoT-Light HER2 CISH test: This test also evaluates if there are too many copies of the HER2 gene in the cancer cells and is reported as positive or negative.
- Inform HER2 Dual ISH test: This test also evaluates if there are too many copies of the HER2 gene in the cancer cells and is reported as positive or negative.
Do symptoms and signs of HER2-positive breast cancer differ from those of HER2-negative breast cancer?
The signs and symptoms for HER2-positive breast cancers are the same as for HER2-negative breast cancers, except for the fact that HER2-positive cancers are likely to grow faster and are more likely to spread. The following are possible signs of breast cancer:
- Thickening or lump in the breast that feels different from the surrounding area
- Inverting of the nipple
- Nipple discharge or redness
- Breast or nipple pain
- Swelling in your armpit or collarbone could mean breast cancer has spread to lymph nodes in that area
- Swelling of part of the breast
- Changes in the skin of the breast
- Skin dimpling (peau d'orange)
- Lymph node changes
What is the treatment for HER2-positive breast cancer?
Your health care team needs to evaluate all therapy and provide guidance in response to all test results available and the specific circumstances of your cancer. Treatment for HER2-positive breast cancer typically involves a combination of chemotherapy and specific drugs used for cancers expressing the HER2 protein:
- Trastuzumab (Herceptin): This is a monoclonal antibody against HER2, as well as the first drug developed that targets the HER2 protein.
- Pertuzumab (Perjeta): This is another monoclonal antibody that targets HER2-positive cancers.
- Ado-trastuzumab emtansine or TDM-1 (Kadcyla): It's a monoclonal antibody that is attached to a chemotherapy drug, emtansine.
- Lapatinib (Tykerb): Medical professionals usually use this kinase inhibitor with chemotherapy or hormone therapy.
- Neratinib (Nerlynx) interferes with the cancer cells' ability to respond to growth signals.
What is the outlook (prognosis) for HER2-positive breast cancer?
As mentioned before, HER2-positive breast cancers are more likely to grow faster and to come back after treatment than cancers that are HER2-negative. However, the development of the drugs discussed above that specifically treat cancers expressing HER2 has led to significant improvements in the outlook for people with HER2-positive breast cancer. While survival rate statistics for breast cancer are not broken down to show rates for HER2-positive cancers, the 5-year survival rate for all localized breast cancers is 99%. However, the 5-year survival rate for metastatic breast cancer is 27%, so it is important to treat HER2-positive breast cancer as early as possible to reduce or prevent spread.
Latest Cancer News
Health Solutions From Our Sponsors
Salerno, K.E. "NCCN Guidelines Update: Evolving Radiation Therapy Recommendations for Breast Cancer." J Natl Compr Canc Netw 15(5S) May 2017: 682-684.
Shield, Kevin D., et al. "Alcohol Use and Breast Cancer: A Critical Review." Alcoholism: Clinical and Experimental Research Apr. 30, 2016.
Top Breast Cancer/Her2Positive Related Articles
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors.
Breast Cancer RecurrenceBreast cancer most often recurs within the first three to five years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Treatment for recurrent breast cancer depends on the initial treatment.
Breast Cancer Symptoms and SignsIn most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
Breast Cancer Facts
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
Estimating Breast Cancer Risk: Questions and AnswersAs breast cancer is the most diagnosed non-skin cancer in American women, it is important to know your breast cancer risk. Risk factors include age, age at menarche, age at first live birth, history of breast abnormalities, breast biopsies, race, and history or breast cancer among first-degree relatives.
Genetic Testing: Families With Breast CancerBreast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Inflammatory Breast CancerInflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
Male Breast CancerMale breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include:
- hormone therapy,
- radiation therapy,
- HER2-targeted therapy,
- neoadjuvant therapy, and
- adjuvant therapy.
Triple-Negative Breast CancerTriple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.